Excel Industries reported mixed financial results for the first quarter of FY27, with operating profits showing resilience while bottom-line earnings contracted due to lower non-operating income. The company’s standalone EBITDA rose marginally to ₹42.4 crore from ₹42.3 crore in the corresponding period last year. This represents an expansion in the EBITDA margin to 14.4% from 13.7% YoY.

However, this operational improvement was not sufficient to offset broader pressures on profitability. Standalone net profit for the quarter fell to ₹29.1 crore, down from ₹33.6 crore recorded in the previous year. The decline in net income occurred against a backdrop of lower top-line growth, with standalone revenue registering at ₹293.7 crore, compared to ₹309.5 crore in the prior year.

On a consolidated basis, total income from operations stood at ₹293.8 crore, a decrease from ₹309.5 crore in Q1FY26. Consolidated net profit after tax was reported at ₹29.5 crore, compared to ₹33.8 crore in the corresponding quarter of the previous fiscal year.

Operational Drivers and Segment Performance

The divergence between operating and net profit figures suggests that non-operating factors impacted the final bottom line. While Excel Industries managed to expand its EBITDA margin by nearly 70 basis points despite a revenue contraction, the net profit margin compressed significantly. The ability to grow EBITDA while revenue fell indicates potential cost efficiencies or favorable product mix shifts at the operating level, though these gains were eroded before reaching the net profit line.

Key operational highlights include:

• Erratic monsoon conditions impacted demand for the Agrochemical Intermediates product group.
• Despite underperformance in Agrochemical Intermediates, Q1 FY27 revenue reached approximately 95% of Q1 FY26 revenue.
• Strong performance from other product groups largely offset the decline in Agrochemical Intermediates.
• Revenue traction was supported by previously announced contract manufacturing projects with superior margin profiles.
• Prudent supply chain management ensured no stock-outs during disruptions amidst global volatility in raw material pricing and availability.

Strategic Developments

The company announced the successful completion of a project for production supplies against a long-term supply agreement on July 23, 2026. This project, which has an annual revenue potential of ₹35–40 crore (excluding cost of raw materials), underscores the company’s execution abilities. Managing Director Ravi Ashwin Shroff stated that this achievement strengthens Excel’s position as a reliable contract manufacturing partner and diversifies its revenue base.

Looking ahead, the company expects near-term demand challenges in Agrochemical Intermediates to persist. However, non-agrochemical product groups are expected to maintain growth momentum. With the dedicated manufacturing setup now commissioned, Excel targets higher volumes under the long-term specialty chemical supply agreement announced in November 2025. Development initiatives in Biocides and Performance Solutions remain on track, with product launches targeted during FY27.

What the Numbers Show

The data highlights a scenario where operational leverage helped stabilize EBITDA, but the overall financial performance was weighed down by the revenue shortfall and subsequent impact on net earnings. Specifically, other income dropped significantly from ₹11.8 crore in Q1FY26 to ₹6.2 crore in Q1FY27, accounting for the majority of the decline in Profit Before Tax (PBT) which fell from ₹44.2 crore to ₹38.5 crore. This indicates that the core operational business (EBITDA) performed better than the headline net profit suggests, as the profit decline was largely driven by non-recurring or non-operational income reductions rather than operational inefficiencies.

Excel Industries will commission a new manufacturing facility with a capacity of 1265 MTPA for a specialty chemical at its Lote site by February 2027. The company disclosed the capacity addition on July 23, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This strategic move aims to diversify the firm's product portfolio, targeting both domestic and international markets without relying on external debt.

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD/PoD2/I/3762/2026 dated January 30, 2026. Surendra Singhvi, Company Secretary, signed the letter submitted to the Listing Departments of BSE Ltd. and National Stock Exchange of India Ltd. The filing details the rationale, investment requirements, and timeline for the proposed capacity addition.

Project Details

The company stated that the existing capacity for this specific product is nil, making this a greenfield addition to its current operations. The investment of ₹5.05 crores will be fully funded through internal accruals, indicating no immediate impact on the company's leverage ratios or need for external capital raising.

Strategic Rationale

Management cited portfolio diversification as the primary driver for this expansion. By introducing a new specialty chemical, Excel Industries seeks to broaden its revenue streams beyond existing offerings. The product is expected to launch in February 2027, immediately following the commissioning of the production capacity.

What the Numbers Show

The decision to fund the ₹5.05 crore project entirely through internal accruals highlights strong cash flow generation capabilities within the organization. This self-funded approach minimizes financial risk while allowing the company to capture market share in the specialty chemicals segment. With target markets spanning both domestic and overseas geographies, the new capacity positions the company to address demand fluctuations in either region, potentially stabilizing revenue contributions from the chemicals division.